Literature DB >> 33980673

Coexistence of optrA and fexA in Campylobacter.

Biao Tang1, Yao Wang2, Yi Luo1, Xue Zheng1, Xiaoxia Qin2, Hua Yang3, Zhangqi Shen4.   

Abstract

Previous studies indicated that Campylobacter has developed several mechanisms that confer resistance to florfenicol, which is used in food animal production. This study describes the coexistence of optrA and fexA in Campylobacter jejuni and Campylobacter coli isolates from pigs and poultry. Moreover, whole-genome sequencing data showed that the two genes are located in various multidrug resistance genomic islands within different regions of the Campylobacter genomes. The emergence of optrA and fexA may support the spread of florfenicol-resistant Campylobacter strains of animal origin.IMPORTANCE Florfenicol is widely used for the treatment of respiratory infections and as a feed additive in food animal production. As a foodborne pathogen, Campylobacter is constantly exposed to florfenicol, and resistance to this antimicrobial agent has increased in recent years. Previous studies indicated that Campylobacter has developed several mechanisms that confer resistance to florfenicol. This study describes for the first time the coexistence of the florfenicol exporter FexA and the ribosomal protective protein OptrA in Campylobacter jejuni isolated from pigs. The two genes were located in various multidrug resistance genomic islands within different regions of the Campylobacter genomes. Although phenicols are not commonly used for the treatment of Campylobacter infections, the extensive use of florfenicol in food animals may play a role in the coselection of multidrug resistance genomic island (MDRGI)-carrying Campylobacter isolates which also exhibited resistance to critically important antimicrobial agents (macrolides, aminoglycosides, and tetracyclines) commonly used for the treatment of human campylobacteriosis.
Copyright © 2021 Tang et al.

Entities:  

Keywords:  Campylobacter; fexA; multidrug resistance; optrA

Year:  2021        PMID: 33980673      PMCID: PMC8125047          DOI: 10.1128/mSphere.00125-21

Source DB:  PubMed          Journal:  mSphere        ISSN: 2379-5042            Impact factor:   4.389


OBSERVATION

Campylobacter is the leading bacterial pathogen that causes diarrheal illness worldwide, with most cases of campylobacteriosis being triggered by Campylobacter jejuni. As a foodborne pathogen, Campylobacter is constantly exposed to multiple antimicrobial agents used during food animal production. Thus, Campylobacter has developed various resistance mechanisms, including the formation of multidrug resistance genomic islands (MDRGIs), for fitness advantage upon exposure to multiple antimicrobial agents (1–4). Florfenicol is a fluorinated thiamphenicol derivative that was exclusively approved as a broad-spectrum antimicrobial agent for the treatment of animals raised for food (5). To date, several mechanisms of antibiotic resistance to florfenicol have been characterized, including the multidrug resistance protein Cfr(C), the multidrug efflux pump RE-CmeABC, and the recently described florfenicol exporter FexA and the ribosomal protective OptrA (4, 6–10). cfr(C), RE-cmeABC, and fexA were characterized in both C. jejuni and Campylobacter coli, whereas optrA was identified only in C. coli (4, 6–10). The phenicol exporter gene fexA is responsible for florfenicol resistance. optrA not only confers resistance to phenicols but also results in elevated MICs of the oxazolidinone linezolid. Although these drugs are not commonly used for the treatment of Campylobacter infections, the extensive use of florfenicol in food animals may play a role in the coselection of MDRGI-carrying Campylobacter isolates, which also exhibit resistance to macrolides, aminoglycosides, and tetracyclines, commonly used for treating human campylobacteriosis (7). Linezolid represents one of the last-resort antimicrobial agents for the treatment of severe infections caused by methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. Thus, the coexistence of these two drug-resistant genes in Campylobacter aggravates the spread of antimicrobial resistance and poses a threat to human health. In this study, the coexistence of optrA and fexA was identified in C. jejuni isolates from pig and C. coli isolates from chicken and duck, and whole-genome sequencing was used to characterize their genetic environment. To determine the presence of optrA, the primers A–F (5′-AGGTGGTCAGCGAACTAA-3′) and A–R (5′-ATCAACTGTTCCCATTCA-3′) (11) were used for PCR analysis of 146 C. coli and 54 C. jejuni strains isolated from poultry and swine farms in Zhejiang and Hunan provinces, China. The optrA sequence was identified in two C. jejuni and five C. coli isolates. Of note, all the strains also contained fexA. To further characterize these seven optrA+ fexA+ isolates and the genetic environment of the genes, a hybrid sequencing strategy using Illumina short-read and MinION long-read technology was used to generate the complete genomes, as previously described (12). Five complete and two draft genome sequences were obtained for further mining (Table 1). In silico multilocus sequence typing of the whole-genome sequencing data showed that these seven isolates belonged to three sequence types (ST), including ST825, ST828, and a new ST (aspA_8, glnA_620, gltA_292, glyA_28, pgm_1072, tkt_668, and uncA_23). Acquired antimicrobial resistance genes can explain the resistance phenotype, including florfenicol resistance, determined by the broth microdilution method (Table 2). Only three and one single nucleotide polymorphisms were detected in the optrA and fexA sequences, respectively, in these seven strains (see Fig. S1 in the supplemental material).
TABLE 1

Isolation and genomic information of optrA+ fexA+ strains

IsolateHostSpeciesGenome length (bp)GC content (%)MLSTaQualityMDRGI length (bp)MDRGI GC content (%)Accession no.
CC19DZ036DuckC. coliChromosome: 1,761,33531.37ST828Completed11,19536.22CP068565
CC19DZ037DuckC. coliChromosome: 1,761,33431.37ST828Completed11,19536.22CP068566
CC19PF050PigC. jejuni1,798,06930.21UnknownDraftJAESVI000000000
CC19PF065PigC. jejuniChromosome: 1,681,08230.57UnknownCompleted18,22334.79CP068567
pPF065-186: 186,64726.41CP068568
pPF065-3: 3,39531.37CP068569
CC19CH074ChickenC. coli1,831,13731.16ST825DraftJAESVJ000000000
CC19CH075ChickenC. coliChromosome: 1,781,47231.47ST825Completed18,55336.36CP068581
pCH075-80: 80,13526.07CP068582
pCH075-4: 4,94429.57CP068583
pCH075-3: 3,40531.01CP068584
pCH075-2: 2,42625.89CP068585
CC19CH076ChickenC. coliChromosome: 1,781,47131.47ST825Completed18,55336.36CP068586
pCH076-80: 80,13126.09CP068587
pCH076-4: 4,94429.57CP068588
pCH076-3: 3,40531.01CP068589
pCH076-2: 2,42625.89CP068590
ZS007Duck meatC. jejuniChromosome: 1,658,56730.55ST10317Completed22,69738.01CP048771
1712SZ1KX20CChickenC. coli1,713,884 31.36ST825Draft9,61136.79JAATKE000000000

MLST, multilocus sequence type.

TABLE 2

Acquired drug resistance genes and MIC of optrA+ fexA+ isolates

IsolateAcquired drug resistance genesMIC (μg/ml) ofa:
CIPNALGENTETCLIERYAZMTELFFC
CC19DZ036tet(L), tet(O), optrA, fexA, catA9, blaOXA-6116640.5324>64>3232>32
CC19DZ037tet(L), tet(O), optrA, fexA, catA9, blaOXA-61161280.5324>64>3232>32
CC19PF050aac(6′)-aph(2′′), aph(3′)-III, aph(2′′)-If, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-465, erm(B)16>128>64>64>32>64>3232>32
CC19PF065aac(6′)-aph(2′′), aph(3′)-III, aph(2′′)-If, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-465, erm(B)16128>64>6416>64>3232>32
CC19CH074aac(6′)-aph(2′′), aph(3′)-III, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-61, erm(B)3264>6464>32643232>32
CC19CH075aac(6′)-aph(2′′), aph(3′)-III, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-61, erm(B)3264>6464>32641616>32
CC19CH076aac(6′)-aph(2′′), aph(3′)-III, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-61, erm(B)32646464>32>643216>32

Abbreviations: CIP, ciprofloxacin; NAL, nalidixic acid; GEN, gentamicin; TET, tetracycline; CLI, clindamycin; ERY, erythromycin; AZM, azithromycin; TEL, telithromycin; FFC, florfenicol. CLSI- or NARMS-approved breakpoint concentrations for resistance, in micrograms per milliliter, are as follows: CIP, 4; NAL, 32; GEN, 4; TET, 16; CLI, 8; ERY, 32; AZM, 1; TEL, 8; FFC, 8.

Isolation and genomic information of optrA+ fexA+ strains MLST, multilocus sequence type. Acquired drug resistance genes and MIC of optrA+ fexA+ isolates Abbreviations: CIP, ciprofloxacin; NAL, nalidixic acid; GEN, gentamicin; TET, tetracycline; CLI, clindamycin; ERY, erythromycin; AZM, azithromycin; TEL, telithromycin; FFC, florfenicol. CLSI- or NARMS-approved breakpoint concentrations for resistance, in micrograms per milliliter, are as follows: CIP, 4; NAL, 32; GEN, 4; TET, 16; CLI, 8; ERY, 32; AZM, 1; TEL, 8; FFC, 8. Comparison of nucleic acid homology of fexA and optrA genes in different strains. Download FIG S1, DOCX file, 0.3 MB. C. jejuni CC19PF065 belongs to a new ST (the nearest STs are 8670, 8672, and 10317), and the complete genome was 1,681,082 bp in length, with a GC content of 30.57% (accession no. CP068567). optrA along with its upstream phenicol exporter fexA and the gene hp, which encodes a hypothetical protein, were located within a 18,223-bp MDRGI with 34.79% GC content. The formed the MDRGI tet(O)-hp-catA9-aac(6′)-aph(2′)-ISL3-IS481-ΔkdsB-matE-gph-IS481-hp-fexA-hp-optrA-IS1216E-tet(L) (Fig. 1) was inserted into the C. jejuni housekeeping genes, between repA and agrC. In addition to fexA and optrA, this MDRGI also contained other genes conferring resistance to tetracycline and aminoglycosides. Moreover, ΔkdsB (3-deoxy-manno-octulosonate cytidylyltransferase), matE (multiantimicrobial extrusion protein), and gph (phosphoglycolate phosphatase) were flanked by the insertion sequence IS481 in the same orientation. The segment IS481-ΔkdsB-matE-gph-IS481 (3,709 bp; 36.88% GC content) exhibited 78.3% nucleotide sequence identity to the corresponding region of Helicobacter cholecystus strain NCTC 13205 (accession no. LR134518), with matE encoding a novel MATE family efflux transporter, most likely from Helicobacter (Fig. S2).
FIG 1

Genetic environment of optrA in the genomes of C. jejuni isolates and comparison of the optrA-carrying regions. Arrows indicate the transcription direction. Regions of >90% homology are marked with gray shading. Genes are differentiated by different colors.

Genetic environment of optrA in the genomes of C. jejuni isolates and comparison of the optrA-carrying regions. Arrows indicate the transcription direction. Regions of >90% homology are marked with gray shading. Genes are differentiated by different colors. (A) Comparative analysis of ΔkdsB-matE-gph regions between strain Z65 CC19PF065 and Helicobacter cholecystus NCTC 13205. (B) Phylogenetic analysis of MatE protein of C. jejuni Z65 CC19PF065. Download FIG S2, DOCX file, 0.3 MB. C. jejuni ZS007 belonged to ST10317, with a complete genome 1,658,567 bp in length and a GC content of 30.55% (accession no. CP048771). This strain was previously reported to contain fexA. Here, the optrA containing MDRGI was found to be 22,697 bp in length (38.01% GC content) (Table 1). The order of gene content was tet(O)-IS1595-hp-hypA-hp-cat-aph(3′)-III-hp-IS21-ant(9)-ant(6)-Ia-Δtet(O)-hp-catA9-IS1216E-ISL3-hp-fexA-hp-optrA-IS1216E-tet(L), which was inserted between repA and agrC. The fragment hp-fexA-hp-optrA-IS1216E-tet(L) was the same as that from C. jejuni CC19PF065. The segment IS1595-hp-hypA-hp-cat-aph(3′)-III-hp-IS21 showed 98.92% nucleotide sequence identity to the corresponding region of the C. jejuni strain BC chromosome (accession no. CP032522). In addition, a novel optrA-containing MDRGI was also characterized in C. coli by comparing the results from published studies (7, 9). According to the sequencing results, C. coli CC19CH075 and CC19CH076 belonged to ST825, and the complete genome sequences were 1,781,472 bp (accession no. CP068581) and 1,781,471 bp (accession no. CP068586) in length, with a GC content of 31.47% (Table 1). In total, 60 single nucleotide polymorphisms and seven gaps were found between the two strains. The order of gene content was tet(O)-hp-ant(9)-hp-erm(B)-hp-hp-ant(6)-Ia-Δtet(O)-hp-catA9-IS1216E-ISL3-hp-fexA-hp-optrA-IS1216E-tet(L), which was inserted between porA and agrC. By comparing with the segment from C. jejuni ZS007, hp-ant(9)-hp-erm(B)-hp-hp was found to be replaced by IS1595-hp-hypA-hp-cat-aph(3′)-III-hp-IS21-ant(9) in C. coli strains CC19CH075 and CC19CH076. C. coli CC19DZ036 and CC19DZ037 belong to ST828, and the complete genomes were 1,761,335 and 1,761,334 bp in length, with a GC content of 31.37% (Table 1) (accession no. CP068565 and CP068566, respectively). In total, only three gaps difference were found between the two strains. The order of gene content was tet(O)-hp-catA9-IS1216E-hp-fexA-hp-optrA-IS1216E-tet(L), which was inserted between nfnB and smc. This study revealed that the emerging gene optrA is associated with various MDRGIs in C. jejuni. Moreover, the core segment fexA-hp-optrA-IS1216E was identified in both C. jejuni and C. coli, which agrees with previous reports (7). Of note, the optrA-containing MDRGIs varied from 9,611 to 22,697 bp and were inserted into different regions over the genomes of Campylobacter, all of which contained tet(O) and tet(L) at the two ends. The GC content of these MDRGIs ranged from 34.79% to 38.01%, which is different from the GC content of the Campylobacter genome (∼31.0%), suggesting that Campylobacter might have obtained these MDRGIs from other species. There were 12 antimicrobial resistance genes in MDRGI, including aac(6′)-aph(2′′), aph(3′)-III, aph(2′′)-If, ant(6)-Ia, tet(L), tet(O), optrA, fexA, cat, catA9, blaOXA-465, and erm(B), which were resistant to aminoglycosides, tetracyclines, phenicol, and macrolides. All of these antibiotics were used for the prevention and treatment of infections in farm animals in China. In addition, the GC content within several MDRGIs was not evenly distributed, and the presence of multiple insertion sequences suggested that their integration may have occurred through a multistep process. Therefore, MDRGI in Campylobacter was likely to be the product of multiple-antibiotic coselection. Due to the use of florfenicol in livestock and poultry production, the emergence of fexA and optrA could confer a fitness advantage under selection pressure, which will support the spread of fexA and optrA and their associated MDRGIs through Campylobacter natural transformation.
  12 in total

1.  Emergence of a plasmid-borne multidrug resistance gene cfr(C) in foodborne pathogen Campylobacter.

Authors:  Yizhi Tang; Lei Dai; Orhan Sahin; Zuowei Wu; Mingyuan Liu; Qijing Zhang
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

2.  A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.

Authors:  Yang Wang; Yuan Lv; Jiachang Cai; Stefan Schwarz; Lanqing Cui; Zhidong Hu; Rong Zhang; Jun Li; Qin Zhao; Tao He; Dacheng Wang; Zheng Wang; Yingbo Shen; Yun Li; Andrea T Feßler; Congming Wu; Hao Yu; Xuming Deng; Xi Xia; Jianzhong Shen
Journal:  J Antimicrob Chemother       Date:  2015-05-14       Impact factor: 5.790

3.  Report of ribosomal RNA methylase gene erm(B) in multidrug-resistant Campylobacter coli.

Authors:  Shangshang Qin; Yang Wang; Qijing Zhang; Maojun Zhang; Fengru Deng; Zhangqi Shen; Congming Wu; Shaolin Wang; Jianzhong Zhang; Jianzhong Shen
Journal:  J Antimicrob Chemother       Date:  2013-12-13       Impact factor: 5.790

4.  Dissemination of erm(B) and its associated multidrug-resistance genomic islands in Campylobacter from 2013 to 2015.

Authors:  Dejun Liu; Fengru Deng; Yanan Gao; Hong Yao; Zhangqi Shen; Congming Wu; Yang Wang; Jianzhong Shen
Journal:  Vet Microbiol       Date:  2017-04-12       Impact factor: 3.293

5.  Emerging erm(B)-Mediated Macrolide Resistance Associated with Novel Multidrug Resistance Genomic Islands in Campylobacter.

Authors:  Dejun Liu; Weiwen Liu; Ziquan Lv; Junjie Xia; Xing Li; Yuxin Hao; Ying Zhou; Hong Yao; Zhihai Liu; Yang Wang; Jianzhong Shen; Yuebin Ke; Zhangqi Shen
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 6.  Molecular basis of bacterial resistance to chloramphenicol and florfenicol.

Authors:  Stefan Schwarz; Corinna Kehrenberg; Benoît Doublet; Axel Cloeckaert
Journal:  FEMS Microbiol Rev       Date:  2004-11       Impact factor: 16.408

7.  Emergence of the Phenicol Exporter Gene fexA in Campylobacter coli and Campylobacter jejuni of Animal Origin.

Authors:  Dejun Liu; Xing Li; Yang Wang; Stefan Schwarz; Jianzhong Shen
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  Novel insertion sequence ISChh1-like mediating acquisition of optrA gene in foodborne pathogen Campylobacter coli of swine origin.

Authors:  Yizhi Tang; Yan Lai; Xingyuan Wang; Changwei Lei; Chao Li; Linghan Kong; Yulong Wang; Hongning Wang
Journal:  Vet Microbiol       Date:  2020-11-25       Impact factor: 3.293

9.  Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans.

Authors:  Tao He; Ran Wang; Dejun Liu; Timothy R Walsh; Rong Zhang; Yuan Lv; Yuebin Ke; Quanjiang Ji; Ruicheng Wei; Zhihai Liu; Yingbo Shen; Gang Wang; Lichang Sun; Lei Lei; Ziquan Lv; Yun Li; Maoda Pang; Liyuan Wang; Qiaoling Sun; Yulin Fu; Huangwei Song; Yuxin Hao; Zhangqi Shen; Shaolin Wang; Gongxiang Chen; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Nat Microbiol       Date:  2019-05-27       Impact factor: 17.745

10.  Emergence of a Potent Multidrug Efflux Pump Variant That Enhances Campylobacter Resistance to Multiple Antibiotics.

Authors:  Hong Yao; Zhangqi Shen; Yang Wang; Fengru Deng; Dejun Liu; Gaowa Naren; Lei Dai; Chih-Chia Su; Bing Wang; Shaolin Wang; Congming Wu; Edward W Yu; Qijing Zhang; Jianzhong Shen
Journal:  mBio       Date:  2016-09-20       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.